title: Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit.
abstract: The merozoite surface protein 1 (MSP-1) is expressed in all Plasmodium species and is considered a major malaria vaccine candidate. We found that MSP-1 from Plasmodium vivax (PvMSP-1) contains a region of significant sequence homology with the 190L subunit vaccine derived from the P. falciparum MSP-1. The fragment, termed Pv200L, was expressed as a recombinant protein in Escherichia coli (rPv200L) and used to asses its immunologic relevance as a vaccine target. A cross-sectional, seroepidemiologic study conducted in Buenaventura, Colombia showed that 52.2% (95% confidence interval [CI] = 39.8-64.3) of individuals previously exposed to P. vivax and 72.8% (95% CI = 61.8-82.1) of P. vivax-infected patients had IgG antibodies to rPv200L. Immunization of BALB/c mice and Aotus monkeys induced IgG antibodies (titer > 10(6)) that cross-reacted with P. vivax parasites. Immunized monkeys displayed partial protection against a challenge with P. vivax blood stages. Our results suggest that Pv200L is a new malaria vaccine subunit and deserves further testing.
authors.affiliation: Instituto de Inmunología and Fundacion Centro de Primates, Universidad del Valle, Cali, Colombia.
authors.forename: Augusto
authors.initials: A
authors.lastname: Valderrama-Aguirre
authors.forename: Gustavo
authors.initials: G
authors.lastname: Quintero
authors.forename: Andrés
authors.initials: A
authors.lastname: Gómez
authors.forename: Alejandro
authors.initials: A
authors.lastname: Castellanos
authors.forename: Yobana
authors.initials: Y
authors.lastname: Pérez
authors.forename: Fabián
authors.initials: F
authors.lastname: Méndez
authors.forename: Myriam
authors.initials: M
authors.lastname: Arévalo-Herrera
authors.forename: Sócrates
authors.initials: S
authors.lastname: Herrera
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood*; D000953:Antigens, Protozoan / Q000737:chemistry / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D000954:Antigens, Surface / Q000737:chemistry / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D002427:Cebidae; D003105:Colombia / Q000453:epidemiology; D003430:Cross-Sectional Studies; D004926:Escherichia coli / Q000235:genetics / Q000378:metabolism; D006801:Humans; D007114:Immunization; D007074:Immunoglobulin G / Q000097:blood; D017780:Malaria Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D016780:Malaria, Vivax / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control*; D020066:Merozoite Surface Protein 1 / Q000737:chemistry*; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D010966:Plasmodium vivax / Q000276:immunology / Q000472:pathogenicity; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D016036:Seroepidemiologic Studies
chemical_list: D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D000954:Antigens, Surface; D007074:Immunoglobulin G; D017780:Malaria Vaccines; D020066:Merozoite Surface Protein 1; D011994:Recombinant Proteins; C073018:Pv200 antigen, P vivax